Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iSERA LifesciencesBOM:534920 20 Current Ratio is 6.63 as of Mar. 2026, which is 285% above its 10-year median of 1.72. GuruFocus rates BOM:534920 with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 2,876 Software companies, iSERA Lifesciences ranks better than 91.45% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. iSERA Lifesciences's current ratio for the quarter that ended in Mar. 2026 was 6.63.
iSERA Lifesciences has a current ratio of 6.63. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for iSERA Lifesciences's Current Ratio or its related term are showing as below:
BOM:534920'
s Current Ratio Range Over the Past 10 Years
Min: 0.18 Med: 1.72 Max: 33.63
Current: 6.63
During the past 13 years, iSERA Lifesciences's highest Current Ratio was 33.63. The lowest was 0.18. And the median was 1.72.
BOM:534920's Current Ratio is ranked better than 91.45% of 2876
companies
in the Software industry
Industry Median: 1.8
vs BOM:534920: 6.63
iSERA Lifesciences (BOM:534920) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
iSERA Lifesciences Current Ratio Related Terms
iSERA Lifesciences Current Ratio Historical Data
* Premium members only.
The historical data trend for iSERA Lifesciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:534920 vs IBM, ACN, FISV: Current Ratio Comparison
For the Information Technology Services subindustry, iSERA Lifesciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iSERA Lifesciences Current Ratio vs Software Industry
For the Software industry and Technology sector, iSERA Lifesciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where iSERA Lifesciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iSERA Lifesciences (BOM:534920) has a Current Ratio of 6.63 as of Mar. 2026. This is 285% above median its historical median of 1.72. Over the past decade, iSERA Lifesciences' Current Ratio has ranged from 0.18 to 33.63. According to the industry distribution chart, iSERA Lifesciences ranks #246 out of 2876 companies in the Software industry, placing it in the top 8.6%.
Is iSERA Lifesciences' Current Ratio too high?
iSERA Lifesciences' current Current Ratio of 6.63 is 285% above median its 10-year median of 1.72. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 33.63. The Software industry median Current Ratio is 1.80. iSERA Lifesciences' value of 6.63 is 268.3% above this industry median. Based on the distribution chart, iSERA Lifesciences ranks #246 out of 2876 companies in the Software industry, which is in the top quartile — a strong position relative to peers. Overall, iSERA Lifesciences has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does iSERA Lifesciences' Current Ratio compare to IBM and ACN?
According to the Software industry distribution chart, iSERA Lifesciences ranks #246 out of 2876 companies for Current Ratio. This places iSERA Lifesciences in the top 9% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.80. iSERA Lifesciences' value of 6.63 is 268.3% above this benchmark. Historically, iSERA Lifesciences' own Current Ratio has ranged from 0.18 to 33.63 over the past decade. While the company's 10-year median is 1.72 vs. the industry median of 1.80, iSERA Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Software company?
The median Current Ratio among Software companies is 1.80, based on 2,876 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iSERA Lifesciences's current Current Ratio of 6.63 is 268.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Software industry, the median Current Ratio is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iSERA Lifesciences's current Current Ratio is 6.63, which is 285% above median its own 10-year median of 1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iSERA Lifesciences stock overvalued right now?
iSERA Lifesciences (BOM:534920) has a current Current Ratio of 6.63. The current Current Ratio is 6.63, which is 285% above median its 10-year median of 1.72 and 268.3% above the Software industry median of 1.80. iSERA Lifesciences' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For iSERA Lifesciences (BOM:534920), the current Current Ratio is 6.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
iSERA Lifesciences Ltd, formally known as Covidh Technologies Ltd, is a technology services provider. The company provides IT and IT-enabled services. It derives revenue majorly from the sale of IT and IT-enabled services and Hardware.
20GF Score
Get the complete analysis for BOM:534920
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:534920 has been successfully added to your 
